2 weeks Ago By ABMN Staff
Long Focus Capital Management LLC increased its stake in shares of Adaptimmune Therapeutics plc ( NASDAQ:ADAP – Free Report ) by 15.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,346,417 shares of the biotechnology company’s stock after purchasing an additional 1,662,184 shares during the quarter.
Long Focus Capital Management LLC owned approximately 5.00% of Adaptimmune Therapeutics worth $12,037,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock.
Columbia Advisory Partners LLC bought a new position in shares of Adaptimmune Therapeutics in the 1st quarter valued at $25,000. JTC Employer Solutions Trustee Ltd bought a new position in Adaptimmune Therapeutics in the 1st quarter valued at approximately $41,000. Twin Focus Capital Partners LLC acquired a new stake in Adaptimmune Therapeutics during the 4th quarter worth approximately $44,000.
Boulder Hill Capital Management LP acquired a new position in Adaptimmune Therapeutics in the 1st quarter valued at approximately $143,000. Finally, Renaissance Technologies LLC raised its stake in shares of Adaptimmune Therapeutics by 28.3% during the second quarter.
Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after acquiring an additional 394,566 shares during the last quarter. Institutional investors own 31.37% of the company’s stock.
Adaptimmune Therapeutics Price Performance Shares of ADAP opened at $0.94 on Friday. The firm has a market cap of $231.
28 million, a PE ratio of -1.27 and a beta of 2.21.
Adaptimmune Therapeutics plc has a 52-week low of $0.42 and a 52-week high of $2.05.
The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.09 and a current ratio of 3.
09. The business’s 50 day moving average price is $1.13 and its two-hundred day moving average price is $1.
15. Analysts Set New Price Targets ADAP has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $4.
00 price target on shares of Adaptimmune Therapeutics in a research report on Tuesday, August 13th. Scotiabank started coverage on shares of Adaptimmune Therapeutics in a research report on Thursday, May 30th. They set a “sector outperform” rating and a $3.
15 target price for the company. Finally, StockNews.com upgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 13th.
Check Out Our Latest Stock Report on Adaptimmune Therapeutics Adaptimmune Therapeutics Company Profile ( Free Report ) Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. Recommended Stories Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
